Abstract
Venous thromboembolism (VTE) is particularly common in cancer patients. Among all patients with VTE, 20% have underlying active malignancy. VTE may be the presenting sign of an occult malignancy, and 10% of patients with idiopathic VTE develop cancer within 2 years. Among hospitalized cancer patients, the cumulative incidence of deep venous thrombosis (DVT) has been reported at 4.6%. On the other hand, up to 50% of cancer patients were found to have evidence of DVT at autopsy. Compared to controls, patients with cancer have a higher risk of first and recurrent VTE, as well as bleeding on anticoagulants.
Currently, the gold standard of VTE treatment is low-molecular-weight heparin, but the results of ongoing trials and a better understanding of bleeding risks related to the pharmacodynamic interaction between direct acting anticoagulants with chemotherapy and better evidence of clinical safety could lead to a change in the therapeutic approach to this pathology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, MASTER Investigators, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93:273–8. https://doi.org/10.3324/haematol.11458.
Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92–5. https://doi.org/10.1038/sj.bjc.6601964.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–46. https://doi.org/10.1002/cncr.23062.
Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999;11:105–10. https://doi.org/10.1053/clon.1999.9023.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. https://doi.org/10.1093/eurheartj/ehw211.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50. https://doi.org/10.1056/NEJM200012213432504.
Kwaan H, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis and cancer. Semin Thromb Hemost. 2003;29:283–90. https://doi.org/10.1055/s-2003-40966.
Lee AY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137–45. https://doi.org/10.1055/s-2007-994915.
Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465–73. https://doi.org/10.1038/sj.neo.7900263.
Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–82. https://doi.org/10.1055/s-2007-994919.
Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992;81:480–8. https://doi.org/10.1111/j.1365-2141.1992.tb02978.x.
Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in the woman. Arch Intern Med. 1996;156:1806–10. https://doi.org/10.1001/archinte.1996.00440150056006.
Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e19–26. https://doi.org/10.2459/JCM.0000000000000377.
Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e93–e104. https://doi.org/10.2459/JCM.0000000000000383.
Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303. https://doi.org/10.1093/annonc/mdj068.
Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15:482–9. https://doi.org/10.1093/eurjhf/hft008.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52. https://doi.org/10.1016/j.chest.2015.11.026.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–204. https://doi.org/10.1200/JCO.2013.49.1118.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7. https://doi.org/10.1182/blood-2007-10-116327.
Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81–91. https://doi.org/10.1007/s11239-015-1313-4.
Escalante CP, Zalpour A, Song J, Richardson MN, Lam T, Halm J, et al. Practice patterns and outcomes of rivaroxaban usage in patients with cancer. J Clin Oncol. 2016;34(26):194. https://doi.org/10.1200/jco.2016.34.26_suppl.194.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. https://doi.org/10.1056/NEJMoa025313.
van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;01:762. https://doi.org/10.1160/TH08-09-0563.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–6. https://doi.org/10.1200/JCO.2014.59.7351.
Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475–83. https://doi.org/10.1378/chest.14-0402.
Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37–46. https://doi.org/10.1016/S2352-3026(14)70018-3.
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. https://doi.org/10.1161/CIRCULATIONAHA.113.004450.
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372–80. https://doi.org/10.1124/jpet.111.180240.
Harvey D, Morgan E. Cancer, inflammation, and therapy: effects on cytochrome p450–mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449–57. https://doi.org/10.1038/clpt.2014.143.
Trials: NCT 02048865, NCT 02073682, NCT 01708850, and NCT 01727427. [Online] Available at: https://www.clinicaltrials.gov/.
Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–86. https://doi.org/10.1001/jama.2015.9243.
Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22:997–1002. https://doi.org/10.1007/s11606-007-0228-y.
Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. https://doi.org/10.1186/1477-9560-11-21.
Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150–7. https://doi.org/10.1160/TH14-11-0977.
Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91. https://doi.org/10.1111/jth.13153.
van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12:1116–20. https://doi.org/10.1111/jth.12605.
Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582–9. https://doi.org/10.1016/j.thromres.2015.07.011.
Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of Hokusai-venous thromboembolism study – methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–94. https://doi.org/10.1111/jth.12230.
Raskob GE, Van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379–87. https://doi.org/10.1016/S2352-3026(16)30057-6.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24. https://doi.org/10.1056/NEJMoa1711948.
Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19:82–93. https://doi.org/10.1634/theoncologist.2013-0239.
Schulman S, Shrum J, Majeed A. Management of bleeding complications in patients with cancer on DOACs. Thromb Res. 2016;140(Suppl 1):S142–7. https://doi.org/10.1016/S0049-3848(16)30113-X.
Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122:2310–7. https://doi.org/10.1182/blood-2013-04-460162.
Parsad S, Ratain MJ. Drug-drug interactions with oral antineoplastic agents. JAMA Oncol. 2017;3:736–8. https://doi.org/10.1001/jamaoncol.2016.3323.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Maurea, N., Caronna, A., Mouhayar, E.N. (2019). Venous Thromboembolism. In: Russo, A., Novo, G., Lancellotti, P., Giordano, A., Pinto, F. (eds) Cardiovascular Complications in Cancer Therapy. Current Clinical Pathology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-93402-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-93402-0_15
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-93401-3
Online ISBN: 978-3-319-93402-0
eBook Packages: MedicineMedicine (R0)